Abstract
The pairing of Sophora flavescens and Fructus Ligustri lucidi is taken from Shi Jinmo Medicine. The idea behind this pairing was inspired by the similarity in pharmacological effects of the two herbal drugs, both of which are known to be effective in the treatment and protection against liver fibrosis. To quantitatively study the extent of the interaction between these drugs and the effect of pairing on the treatment of liver fibrosis, an animal model of liver fibrosis mice was established by intraperitoneal injection of low-dose carbon tetrachloride. The drugs were then administered individually, or in predefined compatibility ratio pairs, by gavage, and the effects on indexes of liver fibrosis were observed. The multisynthetic index method was adopted using Matlab software in order to construct a three-dimensional response surface map of the integration effect and conduct interaction analysis of Sophora flavescens and Fructus Ligustri lucidi. The quadratic surface fitting pattern was designed by quadratic regression to determine the optimal range of each drug. The obtained results show that when the compatibility ratio of Sophora flavescens-Fructus Ligustri lucidi drug pairs is less than or equal to 1:1, their therapeutic effect is enhanced by synergy (interaction value ranging between -0.2 and -1). Overall, the synergy of the high-dose drug pairs is stronger than that of the low-dose drug pairs. The optimal dose ranges are 6~12 g and 8~17 g for Sophora flavescens and Fructus Ligustri lucidi, respectively.
Highlights
A drug pair is a relatively fixed combination of two compatible medicines that interact synergistically in the treatment of particular ailments and infections
We investigate the dose-effective relationship between Sophora flavescens and Fructus Ligustri lucidi, the two components of an herbal drug pair commonly used in traditional Chinese medicine (TCM) to treat hepatic fibrosis
Blood liver related indicators were used to examine the therapeutic effects of Sophora flavescens and Fructus Ligustri lucidi on liver fibrosis in mice
Summary
A drug pair is a relatively fixed combination of two compatible medicines that interact synergistically in the treatment of particular ailments and infections. Hepatic fibrosis refers to the proliferation of connective tissue in the liver caused by varieties in that areas. It is a collection of various types of chronic liver diseases that lead to liver pathogenic factors, leading to pathological excessive deposition of diffuse extracellular matrix in those areas. Liver fibrosis may be chemically induced in animals using hepatotoxic agents, such as paracetamol, galactosamine, thioacetamide, and carbon tetrachloride (CCl4). The most commonly used agent is CCl4, as it processes the greatest potency for causing liver damage and fibrosis in animals. When carbon tetrachloride (CCl4) enters the Evidence-Based Complementary and Alternative Medicine
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
